Product1 distinct publisher3 min readPublished
Healthwatch England says the 27 AI scribes now writing notes across the NHS in England are muddling drug names and diagnoses, and with no device classification from the MHRA, the last check is the patient.
The Product Desk · Product desk

Compiled by The Product DeskSomething wrong?How this is made
The failure lands in the two seconds a clinician spends scanning a summary before signing it. A fluent, plausible note is exactly what these systems produce, which is why a wrong one survives that glance [12]. The cases the watchdog collected involved a real sentence coming out slightly wrong, not an invented fact [13], and slightly wrong is enough when the sentence names a drug.
The other examples make the pattern legible. One summary left out a consultant's instruction that the patient should seek a repeat prescription for migraine medication [5]. Another recorded a doctor telling a patient to continue their Prozac when that doctor had neither prescribed it nor discussed it [6]. Counting the drug swap, three of the four documented errors turn on medication [1]. Each one is the kind of error a demo would miss, because on the page it doesn't look like a defect.
The scribe drafts, the clinician reviews, and the record is assumed safe, but the watchdog found otherwise: "These inaccuracies may persist in their records if the patient doesn't catch them" [7]. The working verification loop is a person reading their own letter at home, which is the one reader with no way of knowing what the consultation established. Rachel Power, chief executive of the Patients Association, is among those raising it, alongside clinicians including the London GP Shier Ziser Dawood and Charlotte Blease of Uppsala University in Sweden [14]. The objection is less to the technology than to its arrival without a safety net [15].
The regulatory mechanism explains how that happened. MHRA guidance published in August sets the line: a system that only transcribes what was said is not a medical device, while one that suggests a diagnosis or a treatment may be, which loads enormous weight onto how a vendor describes its own product [9]. A scribe sold as passive transcription skips a process a clinical assistant would have to complete [10]. Meanwhile documentation is the administrative burden doctors complain about most, and anything that reliably removes an hour of typing a day gets adopted whether or not it has been assessed [11].
For anyone rolling out a summarizer into a system of record, the useful grid has two axes. Does the output become durable and authoritative once written, and does a human who knows the ground truth read it before it commits? Notes that go nowhere and get checked are cheap either way. The dangerous quadrant is durable and unchecked, and NHS scribes sit in it: the artefact is the clinical record and the letter to the patient [3], and the only reliable reader is downstream of the truth.
The fix comes with a cost, and it's worth being direct about it. Assign the verification read to someone who has the source material in front of them, and accept that this gives back part of the hour you bought. The watchdog's own remedy, telling patients a scribe was used and handing them the notes to check [16], turns an accidental safeguard into a designed one, but it does not move the work to someone better placed to do it.
A buyer can settle this before signing. Ask what share of notes are corrected before sign-off and who did the correcting. Time saved per clinic is the number the vendor will bring to the meeting.
Ranked by verification strength, evidence, and original report placement.
A patient in England was told they had demyelination, the nerve damage underlying conditions including multiple sclerosis, when the test result had actually read "null demyelination" and an AI scribe dropped the word that reversed the meaning.
Healthwatch England, the statutory patient watchdog, warned that tools transcribing consultations for GPs and hospital doctors are getting drug names and diagnoses wrong, and that patients are often the ones who notice. The warning was reported by the Guardian.
Twenty-seven different AI scribes are in use across the health service in England; they sit in the consulting room, listen, and produce the note that goes into the record and the letter that goes to the patient.
One scribe swapped a prescribed drug for a different one with a similar name.
One summary omitted a consultant's instruction that the patient should seek a repeat prescription for migraine medication.
Another scribe recorded a doctor telling a patient to continue their Prozac, when that doctor had neither prescribed it nor discussed it.
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 31, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
leadership
Healthwatch finds patients catching the AI scribe errors their clinicians missed1 distinct publisher
product
Pennsylvania's Snap case makes an App Store questionnaire the alleged lie1 distinct publisher
product
Cinemas, classrooms and ICE: smart glasses now need a venue-policy contingency1 distinct publisher
invest
CNN's editorial-board trial balloon is settlement currency, not governance1 distinct publisher
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Attributable but second-hand
Every fact here arrives through one relay — The Next Web summarising the Guardian summarising Healthwatch England — and none of the three layers offers a document, a product name or a rate. The individual errors are specific enough to be checkable in principle: "null demyelination", a similar-name drug swap, a Prozac instruction never given. What is missing is any denominator, any statement from the MHRA or NHS England, and any indication of how the watchdog collected the cases.
Deployed at national scale, unmeasured in volume
Twenty-seven products in consulting rooms across NHS England is not a pilot count, and the errors surfaced from real consultations with real prescriptions, which puts this well past the demo stage. But the reporting never says how many practices, clinicians or appointments are involved, or which vendors hold the share. Wide, and of unknown depth.
Four cases carrying a systemic conclusion
The headline generalisation — scribes are getting drug names and diagnoses wrong across the NHS — rests on four anecdotes with nothing to divide them by. That is a modest overstatement rather than a large one, because the two structural facts underneath it are solid and independently significant: twenty-seven products in use, and no device classification. The regulatory gap is real whether the error rate turns out to be one in a hundred notes or one in a hundred thousand; the reporting simply cannot tell you which.
Classification turns on marketing copy
The MHRA's August line rewards a specific word choice: call your product a passive transcriber and you stay outside the device regime, call it a clinical assistant and you face pre-deployment testing. Since the clinical value lies on the regulated side, the pressure runs one way. Set against that, the watchdog's remit is to advocate for patients and the case selection reflects it, and the outlet is aggregating another paper's scoop on a day when a reversed cancer-adjacent diagnosis makes a strong headline.
Named institutions, single channel
What holds this up is attribution: a statutory watchdog, a national regulator, dated guidance, three named individuals. What weakens it is that all of it comes through one outlet reporting another's story, with no vendor identified, no regulator response, and no way to test the four cases or the product count. Enough to act on if you deploy these tools; not enough to quantify the risk.